Inhibition of complement activation in cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 131, Issue 2, 2006, Pages 266-267

  Sellke, Frank W ^a   Boodhwani, Munir ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; MONOCLONAL ANTIBODY; PEXELIZUMAB;

ANTIGEN ANTIBODY REACTION; AORTA VALVE REPLACEMENT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS GRAFT; DRUG INHIBITION; EDITORIAL; HEART INFARCTION; HEART SURGERY; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RISK ASSESSMENT;

ANTIBODIES, MONOCLONAL; AORTIC VALVE; COMPLEMENT INACTIVATING AGENTS; CORONARY ARTERY BYPASS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; SURVIVAL RATE;

EID: 31044431837     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2005.10.019     Document Type: Editorial

References (4)

1. M. Carrier, P. Ménasché, J.H. Levy Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery J Thorac Cardiovasc Surg 131 2006 352 356
2. S.K. Shernan, J.C. Fitch, N.A. Nussmeier Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass Ann Thorac Surg 77 2004 942 949
3. J.P. Matthew, S.K. Shernan, W.D. White Preliminary report of the effects of complement suppression with pexilizumab on neurocognitive decline after coronary artery bypass graft surgery Stroke 35 2004 2335 2339
4. E.D. Verrier, S.K. Shernan, K.M. Taylor Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass a randomized trial JAMA 291 2004 2319 2327